Sanofi SA reported group sales of €8,075 million for the second quarter, an increase of 0.9% on a reported basis. Progress in the quarter was driven by sales of diabetes medicines and its Genzyme subsidiary which has a portfolio of orphan drugs as well as Aubagio for multiple sclerosis.
